Merck KGaA (MRK) Given a €104.00 Price Target by UBS Group Analysts

UBS Group set a €104.00 ($120.93) target price on Merck KGaA (FRA:MRK) in a report released on Monday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.

Other analysts have also issued reports about the stock. DZ Bank restated a neutral rating on shares of Merck KGaA in a report on Tuesday, April 2nd. Sanford C. Bernstein set a €108.00 ($125.58) price objective on shares of Merck KGaA and gave the stock a neutral rating in a report on Monday, April 15th. Barclays set a €82.00 ($95.35) price objective on shares of Merck KGaA and gave the stock a sell rating in a report on Friday, May 3rd. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the stock a neutral rating in a report on Monday. Finally, Kepler Capital Markets set a €110.00 ($127.91) price objective on shares of Merck KGaA and gave the stock a buy rating in a report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average price target of €101.05 ($117.50).

Shares of FRA MRK opened at €92.16 ($107.16) on Monday. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: What is Elliott Wave theory?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.